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Abstract:  Comparative effectiveness research (CER) has assumed an increasing role in drug 
coverage and, in some cases, pricing decisions in Europe, as decision-makers seek to obtain 
better value for money. This issue brief comparatively examines the use of CER across six 
countries—Denmark, England, France, Germany, the Netherlands, and Sweden. With CER 
gaining traction in the United States, these international experiences offer insights and poten-
tial lessons. Investing in CER can help address the current gap in publicly available, credible, 
up-to-date, and scientifically based comparative information on the effectiveness of drugs and 
other health interventions. This information can be used to base coverage and pricing deci-
sions on evidence of value, thereby facilitating access to and public and private investment 
in the most beneficial new drugs and technologies. In turn, use of CER creates incentives for 
more efficient, high-quality health care and encourages development of innovative products 
that offer measurable value to patients.
            
INTRODUCTION
Comparative effectiveness research (CER) has been widely supported by the Obama 
administration, as well as clinicians, insurers, patient groups, and other policymakers 
as a mechanism to improve health outcomes, quality of care, and consumer choice 
by providing comparative information on available health interventions.1 It is also 
considered a way to help focus purchasing and pricing decisions to slow increases 
in health care spending and improve value. In the United States, spending on phar-
maceutical drugs has increased significantly over the last 10 years, accounting for 
almost 13 percent of health care costs, and annual growth in per capita pharmaceu-
tical expenditure has outpaced other industrialized nations, including the United 
Kingdom, Germany, and France.2
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Last year, the American Recovery and 
Reinvestment Act (ARRA) allocated $1.1 billion to 
advance CER in the U.S. In addition, the Patient 
Protection and Affordable Care Act establishes a new, 
nonprofit body, the Patient-Centered Outcomes Research 
Institute. While these pieces of legislation provide sup-
port and guidance for how CER will develop in the U.S., 
questions remain about how it will be implemented and 
used in practice and its potential impact on policy.
Over the last 20 to 30 years, many European 
countries have established CER systems to inform pric-
ing and coverage decisions in health insurance and to 
aid in the development of clinical practice guidelines.3 
These countries use CER to systematically determine the 
relative value provided by new technologies and to give 
providers and patients information for making treatment 
choices.4 This, in turn, serves to encourage the efficient 
and effective use of health technologies and to support 
innovation by identifying and rewarding high-value prod-
ucts. Although CER has been mainly applied to drugs, 
it is increasingly being used to evaluate medical devices, 
treatment procedures, and public health interventions.
In developing and supporting their respective 
CER systems, European countries have faced many of the 
issues currently challenging the U.S. Specific issues that 
hold relevance for the U.S. include the governance of 
CER and, in particular, the scope and authority of a CER 
entity and its relationship to government, stakeholder 
involvement, how CER is conducted and used in cover-
age and pricing decisions, and, how such recommenda-
tions are disseminated to local decision-makers, provid-
ers, and patients.
This issue brief focuses on the use of CER 
in decisions about drug coverage and pricing in six 
European countries (Denmark, England, France, 
Germany, the Netherlands, and Sweden), exploring the 
aforementioned issues. Although there are considerable 
differences between Europe and the U.S., namely around 
the organization and funding of health care, examining 
Europe’s experiences may serve to inform developments 
in the U.S.
CER FUNCTIONS AND GOVERNANCE
Decisions must be made in all third-party payment sys-
tems regarding what drugs to cover and how much to 
pay. When such decisions are based on CER, it typically 
involves two stages: an assessment of a drug’s benefits, 
relative benefits, and costs, followed by an appraisal (i.e., 
interpretation and consideration) of the evidence to 
inform coverage and, sometimes, pricing decisions. These 
two stages may or may not be carried out by the same 
agency (Table 1). In the European countries examined 
in this brief, the CER bodies assume different roles, in 
terms of decision-making authority and relationship to 
government (i.e., whether they are integrated with gov-
ernment or are at an arms-length distance). Some bod-
ies act in a regulatory capacity, making decisions about 
coverage or pricing. Others take an advisory role, making 
coverage or pricing recommendations to government, 
often the Ministry of Health, which then renders cover-
age or pricing determinations. In countries with advisory 
bodies (France, Germany, the Netherlands), the Ministry 
of Health oversees the assessment process or sets priori-
ties for assessment to some degree.5 The bodies can also 
be categorized as those that “produce” CER (England, 
Germany, Sweden)—that is, they conduct evidence syn-
thesis, economic modeling, and other studies—and those 
that mainly “use” existing CER, typically submitted from 
manufacturers, to make coverage recommendations or 
decisions (Denmark, France, the Netherlands).
Sometimes, external organizations are involved 
in assessments. In England, the National Institute for 
Health and Clinical Excellence (NICE), for example, 
coordinates independent reviews conducted by academic 
research centers.6 The use of independent reviews may 
lend greater transparency to the CER process and help to 
prevent or resolve potential disputes because the organi-
zation conducting the assessment is not affiliated with the 
decision process, thereby minimizing perceived conflicts 
of interest.7 However, the use of external organizations 
for assessments can also generate questions about respon-
sibility and accountability.
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use. Despite growing acknowledgement that involvement 
of patients and consumers may improve CER processes, 
few systems have formal mechanisms in place to facilitate 
such participation.
In all of the six countries, manufacturers are gen-
erally involved prior to the assessment process, when they 
submit a dossier of evidence to the review body.10 They 
do not normally participate in the actual assessment or 
appraisal process. Some commentators and analysts have 
argued for earlier and greater industry involvement.11 
For example, early involvement of manufacturers can 
help identify and resolve data gaps or problems at the 
beginning of assessments, thus improving the quality and 
efficiency of the review. However, while involving indus-
try may be beneficial, it can give rise to concerns about 
reduced objectivity of assessments.
Although stakeholder involvement may increase 
the resources and time required to complete assess-
ments, it can enhance the relevance of and trust in the 
CER process. In particular, increased engagement by 
STAKEHOLDER INVOLVEMENT
The guidance and decisions resulting from CER can have 
a significant impact on treatment availability, as well as 
clinical practice. Consequently, in addition to policymak-
ers, a range of stakeholders—physicians, pharmacists, 
health economists, insurance and industry representa-
tives, and patients—are interested in the process and 
want their views to be considered.
An Organization for Economic Cooperation and 
Development study found that patients and consumer 
groups were the least likely stakeholders to be involved in 
the assessment process.8 Increasingly, however, academ-
ics and review bodies in England, Germany, and Sweden 
have recognized the importance of involving patients 
and consumers to provide useful insight into a drug’s 
“real-world” value.9 For example, NICE in England has 
established a Citizens Council to gather public perspec-
tives on key social and ethical issues, such as whether age 
and disease severity should be taken into account when 
NICE makes decisions about treatment availability and 
Table 1. Key Drug Review and Decision-Making Bodies in Select Countries, 2009
Country
Assessment Process Appraisal Process
Review Body Function Role
Relationship to 
Government Coverage and Pricinga
Denmark Reimbursement Committee of the Danish Medicines Agency (DKMA) Coverage Regulatory Integrated DKMA
England National Institute of Health and Clinical Excellence (NICE) Coverage Regulatory Arms-length NICE
France
Evaluation Committee for Medical 
Products of the National Health 
Authority (HAS)
Coverage Advisory
Integrated
Ministry of Health and Sport 
(coverage)
CEPS (pricing)Economic Committee for Health 
Products (CEPS)
Pricing Regulatory
Germany Institute for Quality and Efficiency in Health Care (IQWiG) Coverage Advisory Arms-length
Federal Joint Commission and 
Ministry of Health
Netherlands
Health Care Insurance Board, 
Committee for Pharmaceutical 
Aid (CHF)
Coverage and 
Pricing
Advisory Integrated
Ministry of Health, Welfare, 
and Sport 
(coverage and pricing)
Sweden Dental and Pharmaceutical Benefits Board (TLV)
Coverage and 
Pricing
Regulatory Arms-length
TLV 
(coverage and pricing)
Note: All countries (except France) also have dedicated national agencies that primarily coordinate and disseminate assessment reports on drugs and other health technologies 
and interventions. However, they are not involved in making drug coverage decisions. For further information on these agencies, see M. Velasco Garrido, F. B. Kristensen, and C. 
P. Nielsen et al., Health Technology Assessment and Health Policy-Making in Europe: Current Status, Challenges and Potential (Copenhagen: World Health Organization, 2008). 
a Denmark, England, and Germany operate a free pricing system, with prices generally set by industry. However, manufacturers must notify the DKMA, Department of Health, and 
the Federal Association of Sickness Funds in Denmark, England, and Germany, respectively, with prices. 
Source: C. Sorenson, M. Drummond, and P. Kanavos, Ensuring Value for Money in Health Care: The Role of Health Technology Assessment in the European Union (Copenhagen: 
World Health Organization, 2008).
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stakeholders can improve the quality of assessments, 
lower the number of appeals, and lead to better accept-
ance and use of recommendations.12 
CONDUCTING ASSESSMENTS
Assessments involve many of the same principles and 
processes across the six countries, but they differ in 
some key areas, such as selecting which drugs to review, 
the type and quality of evidence required, and method-
ological approaches (Table 2). Many countries publish 
guidelines outlining their evidence and methodological 
requirements, but the guidelines often vary in detail and 
transparency.13
It typically takes three months to two years to 
review drugs for coverage, raising concerns about delays 
in patients’ access to new drugs. To address this concern 
and facilitate speed to market, France, Germany, and the 
Netherlands have introduced expedited review processes 
for highly innovative drugs or for those treating life-
threatening illnesses. Similarly, England has led efforts to 
shorten reviews by introducing fast-track processes such 
as single technology appraisals that place more emphasis 
on manufacturer data and less on extensive external sys-
tematic review and consultation. These various initiatives 
have allowed some drugs to be available a few months 
after launch. 
DECISION-MAKING AND IMPLEMENTATION
Applying CER to Drug Coverage Decisions
The decision to cover a drug is based on appraisal of 
the evidence. Review bodies employ a variety of crite-
ria to inform coverage decisions (Table 3). In all these 
countries, a drug’s relative therapeutic benefit is the 
most important criterion in determining coverage sta-
tus, followed by cost-effectiveness, which is measured 
using cost per quality-adjusted life year (QALY) ratios.14 
Cost-effectiveness is particularly important for drugs 
that have new indications, are expensive, are expected to 
be widely used, or whose benefits differ by indication or 
patient subgroup.15 England, Germany, the Netherlands, 
and Sweden explicitly use cost-effectiveness in coverage 
decision-making, whereas its role in the review process is 
not always clear in Denmark and France.
Some countries use a cost-effectiveness or price 
threshold to establish whether a drug provides sufficient 
value and to determine coverage status and, in some 
cases, reimbursement levels. A threshold generally repre-
sents the amount of money a society is willing to pay for 
an additional unit of health outcome (i.e., an additional 
QALY). Such “decision rules” are often implicit and 
case-dependent. The value of the annual cost threshold 
varies by country: it is generally set at £20,000–£30,000 
($30,000–$45,000) in England, €20,000 ($30,000) 
in the Netherlands, and 500,000SEK ($62,000) in 
Sweden.16 Following recent changes to IQWiG’s author-
ity to consider costs in its assessments, Germany uses 
prior funding decisions for similar products to determine 
the maximum ceiling reimbursement level for a drug, as 
opposed to a cost per QALY threshold. In several of these 
countries, CER bodies are striving to ensure that the 
threshold effectively captures product value. For example, 
the Netherlands and Sweden are considering adopting a 
revised approach that adjusts the threshold according to 
need or equity considerations, especially for drugs that 
are potentially expensive or address unmet medical needs 
(e.g., cancer drugs and therapies treating rare conditions). 
England recently agreed to extend its threshold for drugs 
aimed at end-of-life care under some circumstances to 
facilitate cancer drug access in the NHS.
Use of Comparative Effectiveness Research in Drug Coverage and Pricing Decisions 5
Table 2. Comparative Drug Review Methods Used in Select Countries, 2008
Denmark England France Germany Netherlands Sweden
Selection 
criteria for 
drugs to review
Every new druga Drugs referred by 
Department of 
Health, which are 
then prioritized 
based on a variety 
of criteria, such 
as health impact, 
disease burden, 
and clinical/policy 
relevance
Every new druga Drugs referred by 
the Federal Joint 
Commission, which 
are considered 
to have potential 
health/cost 
impact, or where 
available evidence 
is inconclusive 
or controversial. 
Typically, these are 
drugs that cannot 
be easily classified 
under the reference 
pricing system.
Drugs that cannot 
be classified under 
reference pricing 
system
Every new druga
Evidence 
requirements
RCT data preferred; 
health economic 
information 
recommended, but 
not required
Source: Evidence 
from manufacturer 
dossier
RCT data preferred; 
health economic 
information 
required 
Source: Systematic 
reviews and 
analyses of clinical 
and economic 
studies; may or 
may not include 
manufacturer data
RCT data preferred; 
health economic 
information 
recommended, but 
not required 
Source: Evidence 
from manufacturer 
dossier
RCT data 
preferred; 
health economic 
information 
required 
Source: 
Systematic 
reviews and 
analyses of 
clinical and 
economic 
studies; may or 
may not include 
industry data
RCT data 
preferred; 
health economic 
information 
required
Source: 
Evidence from 
manufacturer 
dossier
RCT data 
preferred; 
health economic 
information 
required 
Source: 
Systematic 
reviews and 
analyses of 
clinical and 
economic 
studies; may or 
may not include 
manufacturer 
data
Preferred 
or required 
approach 
(for health 
economic 
component)
N/A CEAb
CUA
CEA
CUA 
CMA
Efficiency frontier 
analysis
CEA
CUA
CEA
CMA
Choice of 
comparator
N/A Current best 
alternative or 
routine treatment
Three comparators 
required from same 
therapeutic group:
most frequently 
used
cheapest
most recently 
added to the 
positive list
Most effective 
treatment, most 
widely used, or 
routine treatment
Routine treatment Three comparators 
required from same 
therapeutic group:
routine treatment
nonmedical 
intervention
no treatment
Principal 
outcome 
measures
N/A Mortality
Morbidity
Quality of life
Mortality
Morbidity
Quality of life
Mortality
Morbidity
Quality of life
Mortality
Morbidity
Quality of life
Mortality
Morbidity
Quality of life
Willingness to pay
6 The Commonwealth Fund
Denmark England France Germany Netherlands Sweden
Costs N/A Direct costs
Indirect costs, 
depending upon 
the assessment
Varies
If indirect costs are 
included, must be 
reported separately
Direct costs
Indirect costs
Direct costs
If indirect costs are 
included, must be 
reported separately
Direct costs
Indirect costs
Modeling Yes Yes Yes Yes Yes Yes
Sensitivity 
analysis
Yes Yes Yes Yes Yes Yes
Subgroup 
analyses 
required or 
consideredc
Yes Yes Yes Yes Yes Yes
Equity issues 
consideredd
No Yes No No No Yes, but not clear 
how accounted 
for
a This entails reviewing every new drug dossier submitted by manufacturers to support a coverage decision. Thus, in principal, manufacturers ultimately decide which drugs are 
reviewed. 
b CEA = cost-effectiveness analysis; CMA = cost-minimization analysis; CUA = cost-utility analysis. CEA is the most widely used assessment approach, of which CUA is type 
of CEA. CUA uses quality-adjusted life years (QALYs) as the principal measure of health benefit in economic evaluation, which allows comparison of the value of money of 
different drugs across different therapeutic areas. Efficiency frontier analysis, alternatively, focuses on ascertaining the relative costs and benefits of different drugs within a 
given therapeutic area. For discussion on the methodological merits and demerits of CUA and efficiency frontier analysis, see A. Oliver and C. Sorenson, “The Limitations and 
Challenges to the Economic Evaluation of Health Technologies,” in The Economics of New Health Technologies: Incentives, Organization, and Financing. ed. Joan Costa-Font, 
Christophe Courbage, and Alistair McGuire (Oxford: Oxford University Press, 2009), and M. Drummond and R. Rutten, New Guidelines for Economic Evaluation In Germany and 
the United Kingdom. Are We Any Closer to Developing International Standards? (London: Office of Health Economics, Nov. 2008), available at: www.ohe.org/page/publications/
publication.cfm?catid=35&itemid=624&archive=0. 
c Subgroup analysis is used to explore how cost-effectiveness varies by characteristics of different patients or patient groups eligible for treatment. 
d Includes whether the costs and benefits of available care are equally and fairly distributed among those using a given service. Typically, in CEA, this would translate to each 
additional QALY considered of equal importance for each person, regardless of age, gender, and individual ability or resources to seek care. Currently, however, CER mainly 
focuses on efficiency to maximize population health within available budgets. Even when equity is considered, judgments are usually made implicitly and on a case-by-case basis. 
Source: C. Sorenson, M. Drummond and P. Kanavos, Ensuring Value for Money in Health Care: The Role of Health Technology Assessment in the European Union (Copenhagen: 
World Health Organization, 2008).
As outlined in Table 3, other criteria, such as 
disease burden, may be used to assess the value of a drug. 
Many stakeholders contend that more consideration 
should be given to such factors in coverage decisions 
and that greater transparency and explicitness is needed 
regarding how they factor into the decision process. That 
is, when are such factors considered and what weight are 
they given. This is particularly true of more qualitative 
factors, such as equity.
In all countries, it is rare for an approved drug to 
not be accepted for any level of coverage following review, 
but many are reimbursed with conditions (e.g., for use 
only in certain indications and patient groups) or are sub-
ject to a reference pricing system (in Denmark, Germany, 
and the Netherlands).17,18 This is particularly true 
regarding “me-too” drugs—products that do not offer 
additional benefit compared with similar drugs already 
available. In general, countries are becoming increasingly 
selective in coverage determinations, especially for expen-
sive products, where demonstrating added therapeutic 
benefit or a certain level of innovativeness is increasingly 
required for reimbursement.
In some cases, decision-makers are also mak-
ing coverage conditional on post-market demonstra-
tion of a drug’s costs and benefits. England, France, the 
Netherlands, and Sweden have introduced risk-sharing 
agreements and coverage with evidence development 
(CED) schemes with manufacturers. Risk-sharing agree-
ments allow coverage based on meeting certain, specified 
conditions, such as cost, volume, market share, and cost-
effectiveness targets.19 If the conditions are not met, then 
coverage may be withdrawn or the drug’s price reduced.20 
For example, after NICE controversially recommended 
against the use of various products for multiple sclerosis, 
the government established a risk-sharing scheme with 
manufacturers to supply these treatments on the NHS. 
Under the scheme, patients were monitored annually 
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and the amount paid for the drugs was adjusted on a 
sliding scale if patient outcomes differed from an agreed 
cost per QALY of no more than £36,000 ($59,000). The 
implementation of the scheme, however, has faced mul-
tiple challenges, including slow organization and uptake. 
The CED approach applies a similar strategy. Coverage 
is conditional, based on the collection of post-market 
evidence and reevaluation. These types of approaches 
are particularly suitable for severe conditions or areas of 
high unmet need, high-cost drugs, and situations where 
there is strong political or patient lobbying for access. 
Their overarching aim is to facilitate patient access to 
potentially important new treatments, while duly ensur-
ing that public funding decisions are sufficiently based on 
evidence of value for money.
While the drug assessment and appraisal process 
typically occurs prior to market launch, some countries 
(France, the Netherlands, Sweden) also undertake sys-
tematic reevaluations after drugs have been used in prac-
tice to identify products that do not demonstrate good 
value or those that have become obsolete. This approach 
allows a greater range of drugs to be assessed for value, 
especially considering that in many countries not every 
new drug is reviewed. Evidence from post-market reviews 
can be used to modify pricing and coverage status, where 
appropriate, or to determine areas for disinvestment (i.e., 
removal from list of publicly covered drugs). Denmark 
has recently announced a five-year review of the pric-
ing and coverage status of existing drugs, and Sweden 
has been evaluating all drugs approved prior to 2002.21 
England has also called for greater NICE involvement in 
supporting disinvestment.22 Reevaluation features cen-
trally in risk-sharing agreements and CED, which nor-
mally require pre- and post-market review.
The effective use of CER in drug coverage deci-
sion-making depends on several factors, including:23
the compatibility of the evidence and recommen-•	
dations generated by the assessment and the infor-
mation needs of decision-makers.
the time taken to complete assessment.•	
the transparency of the assessment process, and•	
the level of knowledge or understanding of the •	
assessment process (particularly technical aspects) 
among decision-makers.
Table 3. Key Criteria Used by Countries to Make Drug Coverage Decisions, 2008
Decision criteria Denmark England France Germany Netherlands Sweden
Therapeutic benefit      
Cost-effectiveness *  *   
Necessity (disease burden, severity)  
Availability of treatment alternatives    
Public health impact 
Equity  
Innovative characteristics  
(e.g., ease of use)   
Budget impact   
Ethical/legal considerations  
Feasibility of assessment 
* Unclear if and when cost-effectiveness is considered. 
Source: C. Sorenson, M. Drummond, P. Kanavos. Ensuring Value for Money in Health Care: The Role of Health Technology Assessment in the European Union (Copenhagen: 
World Health Organization, 2008).
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Role of CER in Drug Pricing and  
Cost-Sharing
CER evidence is also employed to support pricing deci-
sions, although its use differs across countries. Such 
evidence more directly influences pricing decisions in 
France, Sweden, and, potentially in the future, England. 
France considers a drug’s comparative therapeutic advan-
tage over existing alternatives within the same indication 
in price negotiations with manufacturers. The greater the 
level of therapeutic improvement, the higher the poten-
tial price relative to similar products. Drugs offering no 
added value over existing comparator products must be 
priced lower to be reimbursed. Sweden uses value-based 
pricing (VBP), adopted in 2002, an approach whereby 
coverage and pricing decisions are made concurrently 
based on an assessment of health needs and cost-effective-
ness. For example, if the drug price requested by a manu-
facturer is unusually expensive in relation to the benefits 
or value provided, the drug may either not be covered 
or its price might be reduced. Moreover, pricing may 
be varied by patient subgroup since those with certain 
diseases may benefit more than others. This approach 
has been heralded as a mechanism to obtain greater 
value from existing pharmaceutical budgets and create a 
stronger link between coverage and pricing decisions.24 
A pilot VBP scheme has also been recently implemented 
in England. In other countries, particularly those with 
reference pricing systems, CER evidence can indirectly 
influence pricing decisions to the extent that it aids in 
forming a judgment about whether or not a drug offers 
additional therapeutic value relative to other, similar 
products (i.e., reference groups). If so, the drug may be 
granted a higher price or coverage level than the reference 
amount.25 In this sense, CER essentially serves as a tool 
for price justification.
Although limited evaluation exists on the effec-
tiveness of using a value-based approach to drug pricing, 
there is some evidence to suggest that higher margins are 
gained by drugs that demonstrate significant advances in 
therapy.26 Moreover, a value-based pricing approach may 
furnish important market signals to industry as to what 
type and level of innovation is most useful and will be 
rewarded.27
CER evidence also influences levels of cost-
sharing in some countries. In France, a drug’s demon-
strated level of therapeutic benefit, coupled with the 
severity of the disease treated, corresponds to different 
levels of copayment borne by the patient.28 For example, 
cost-sharing arrangements range from 35 percent, 65 
percent, and 100 percent, based on “major” or “impor-
tant,” “moderate,” and “weak or “insufficient” benefit, 
respectively. Drugs deemed as irreplaceable and par-
ticularly expensive (e.g., HIV drugs) are covered in full. 
This tiered payment system aims to motivate patients 
(and their physicians) to choose high-value drugs. In 
reference pricing systems, such as in Germany, patients 
are often required to pay any price above the maximum 
reimbursement price (i.e., in the case of premium-priced 
drugs). This approach assumes that some patients will 
be willing to pay for the additional benefits provided by 
higher-priced (i.e., generally newer) drugs. Consumers 
then, in turn, send signals regarding the value they place 
on certain benefits. In practice, however, it is unclear 
that patients have the necessary information and abil-
ity to ascertain the relative benefits across products in a 
meaningful way. It is therefore important for CER infor-
mation to be made widely available and effectively com-
municated to patients and the public. For low-income 
patients, who may not have access to higher-priced 
products, there is generally a low level of cost-sharing. In 
certain cases, low-income patients and other groups (e.g., 
children, people with chronic conditions) are regularly 
exempt from out-of-pocket payments. In Denmark and 
France, complementary private health insurance may also 
cover some or all of the out-of-pocket costs.
Disseminating and Implementing  
Drug Coverage Decisions
In several of the countries, coverage decisions apply 
nationally, but regional or local authorities have some dis-
cretion in implementing national decisions in Denmark, 
England, and Sweden. In Sweden, for example, local 
coverage decisions are often more restrictive than national 
recommendations, in part due to budget constraints.29 
Regional differences in coverage in Denmark and 
England have also resulted in geographical variation in 
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access to some drugs. Such variations can be attributed 
to a lack of sufficient funding to implement the national 
coverage decisions, inadequate or delayed local uptake of 
guidance, poor financial planning by local authorities, 
insufficient health economics expertise among local for-
mulary committees, and divergent local health needs.
Successful dissemination and implementation of 
coverage decisions is a key challenge. Review bodies use 
different strategies to enhance the adoption of drug cov-
erage decisions or recommendations. In England, France, 
Germany, and the Netherlands, review bodies dissemi-
nate information in newsletters, patient information Web 
sites, published guidance, and official national bulletins 
and publications to apprise stakeholders of comparative 
drug information, recent decisions, and policy changes. 
In England and Sweden, experts and formal field-based 
teams are used to promote implementation at the local 
level. Decision-makers in Denmark, England, and 
Sweden use financial strategies, like providing additional 
financial support to regional or local authorities to cover 
the cost of supplying new drugs. Denmark uses decision-
support tools, such as the mini-HTA (health technology 
assessment), to assist local and regional hospital managers 
in setting priorities and budgeting and planning for the 
introduction of new drugs and other health technologies. 
Another strategy used in almost all countries is partici-
pation in international networks, such as the European 
Network for Health Technology Assessment, to facilitate 
methods development and enhance the transferability 
and transparency of CER. 
Regulatory levers have recently been used in 
Denmark and England to reduce geographical variation 
in coverage. In England, for example, it is mandatory for 
NICE recommendations to be implemented within three 
months of dissemination. However, compliance with 
the mandate has been variable, and there is concern that 
these requirements may steer the NHS toward funding 
interventions that NICE assesses and away from other, 
possibly higher priority, investments.30
Overall, successful implementation is facilitated 
when decision-makers are committed to using assess-
ment findings in drug coverage determinations, policy or 
regulatory measures are available to support and enforce 
the uptake of decisions by national and local authorities, 
stakeholders are involved in the assessment process, and, 
assessments and decisions are transparent. Moreover, 
it is important to ensure that all relevant stakeholders 
are informed of decisions and the potential impact on 
care access and delivery. The various means of CER dis-
semination used by these countries serves to ensure that 
providers and patients have access to credible sources of 
evidence-based comparative drug information. Unlike 
the U.S. and elsewhere, direct-to-consumer advertising is 
prohibited across Europe.
CONCLUSIONS AND POLICY IMPLICATIONS 
FOR THE UNITED STATES
CER has assumed an increasing role in drug coverage 
and, in some cases, pricing decisions in Europe. Not only 
does it contribute to evidence-based decision-making, it 
also assists in identifying the drugs that offer the most 
value for money. The six countries reviewed here have 
adopted different approaches to using CER in drug cov-
erage decisions, but all strive to ensure rigorous, relevant, 
and transparent assessments.
Drug reviews are useful only if the resulting 
recommendations are used by policymakers, reflected 
in clinical practice, and support patients’ access to high-
quality and beneficial health services. Consequently, 
many countries have introduced innovative approaches to 
enhance the use and impact of CER in drug reviews and 
improve the coverage decision-making process. Strategies 
such as risk-sharing agreements and CED address the 
inadequacy of data often available at the time of assess-
ments and decrease the time to market for promising new 
drugs. These approaches are sometimes used in conjunc-
tion with post-market review and, in some countries, 
value-based pricing to ensure greater value, efficient use 
of resources, and a more robust assessment process. They 
also help to better align pharmaceutical spending or pur-
chasing decisions with value considerations, and offer sig-
nals to industry on where to focus their CER efforts and, 
more broadly, research and development investments.
International collaboration is another strategy 
that is gaining traction. While there is general consensus 
that the appraisal process should be undertaken within 
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national and local contexts, there are potential efficiencies 
to be gained from enhanced collaboration around assess-
ments. Increased sharing of information (e.g., methods, 
data requirements, results) across countries may save 
costs and reduce duplication. International collaboration 
may also facilitate evidence development for promising 
technologies, where existing data are often limited and 
pooled expertise is increasingly required. Moreover, it can 
support CER capacity building in countries with limited 
experience or without formal systems. The feasibility and 
effectiveness of international collaboration is depend-
ent, however, on addressing potential challenges, such as 
attaining agreement on review priorities and assessment 
perspectives (e.g., societal vs. payer), standardizing meth-
ods, ensuring that supporting studies or assessments meet 
the needs and circumstances of different countries, and 
protecting the confidentiality of commercial data.
Other strategies can improve the timeliness of 
assessments and ensure the implementation of coverage 
decisions, especially at the local level. The introduction of 
expedited or “fast-tracked” review processes has facilitated 
the speed of assessments, as national decision-makers in 
Europe increasingly look to new approaches to ensure 
patient access to important new treatments. A balance 
must be attained, however, between expediting reviews 
and ensuring a robust process. Strategies to support 
effective and timely implementation include the use of 
additional funding and training in financial planning for 
local authorities and mandates for compliance. Countries 
employ a variety of communication media, such as Web 
sites, disease management guides, and lay publications, 
to ensure that patients and providers are informed of the 
outcomes of CER research and have access to up-to-date, 
evidence-based drug- and disease-specific information.
The experiences with CER described in this brief 
offer several potential lessons for the U.S., including the 
following:
In the U.S., there is a lack of publicly available, •	
accessible, and robust comparative information 
on the effectiveness of drugs and other health 
interventions. This gap makes it difficult for clini-
cians, other decision-makers, and patients to make 
informed choices on which interventions work 
best and under what circumstances. To support 
evidence-based decision-making and to meet pub-
lic expectations of safety, effectiveness, and value 
for money, the U.S. needs to invest in CER, as 
other industrialized countries have done.
Currently, while there are no blanket prohibitions •	
in the Patient Protection and Affordable Care Act 
regarding the use of CER by public and private 
payers, it remains to be seen how such research 
will be used in the U.S. Based on the experience 
of Europe, the uptake and impact of CER may 
be limited if it does not have the authority to 
formally link research with policy and practice. 
Establishing a more formal link can improve the 
transparency of coverage decisions in the public 
domain and ensure that such policies are based on 
independent, scientific assessment.
To have the greatest impact on health system per-•	
formance, policymakers should consider extend-
ing CER beyond drugs to a wide range of health 
technologies, health services, and delivery systems. 
Clear and transparent research priorities should be 
set, with stakeholders given a voice in identifying 
areas for review.
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While there is uncertainty regarding the gover-•	
nance, structure, and processes of a formal CER 
enterprise in the U.S., policies and practices in 
other countries highlight the importance of: 
ensuring a level of independence from central 
government and other key stakeholder groups 
(e.g., industry, insurance bodies), establishing 
and maintaining clear lines of accountability and 
transparency, supporting broad stakeholder repre-
sentation and participation, and employing rigor-
ous and explicit methods for evidence generation 
and analysis.
To support robust methods and more effective •	
decision-making, the federal initiative should sup-
port research that is both comprehensive, in terms 
of looking at more complete outcome measures, 
and relevant to real-world clinical decisions. This 
will entail building a robust CER data infrastruc-
ture by using and linking a variety of data sources, 
from electronic health records to large observa-
tional databases. It will also involve collaboration 
among key stakeholders (e.g., governmental bod-
ies, academia, private sector, health associations), 
both nationally and abroad, to facilitate and expe-
dite CER studies. 
Recent innovations to speed up the CER process •	
to facilitate patient access to new drugs, such 
as risk-sharing agreements and CED, could be 
considered or strengthened. CED, in fact, was 
developed originally by the Centers for Medicare 
and Medicaid Services (CMS) and has been sub-
sequently used in a few coverage decisions. In cer-
tain circumstances, relevant decision-makers could 
collaborate with manufacturers prior to a drug 
coming onto the market to ensure that the neces-
sary data are collected to support CER studies. 
NICE has taken this approach on a few occasions. 
CER is only useful to the extent that it is used to •	
improve policy and practice. As such, wide dis-
semination and use of CER findings is essential. 
The U.S. could use CER to improve drug access 
and secure better prices through value-based 
insurance design, tiered benefits, and cost-sharing 
based on effectiveness. CER can also be employed 
to develop practice guidelines or decision tools to 
help providers better match medical care to the 
unique needs of individual patients and to foster 
health research and development toward high-
value, high-impact innovation.
There are indeed clear differences between U.S. 
and European health systems, due in part to divergent 
political and historical traditions, incomes, and cultural 
attitudes. However, faced with the challenges of, as well 
as opportunities for, improving the effectiveness, value, 
and quality of health services, the United States can gain 
valuable insights from international experiences with CER.
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